Mauna Kea Technologies SA manufactures and sells medical devices in Europe, Middle East, Africa, the United States, Canada, and Asia. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables physicians to monitor disease progression over time, assess reactions as they occur, classify areas of uncertainty, and guide surgical procedures, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.…
Mauna Kea Technologies installe Cellvizio en Espagne et à Dubaï pour les kystes pancréatiques
Mauna Kea Technologies (EPA: ALMKT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 56 employees.
The shares were at 0.0875 EUR on 20 November 2026, up 18.2% over 52 weeks. Its 52-week range is 0.0692 EUR to 0.2315 EUR: the price is 62.2% below the high and 26.4% above the low.
Its market capitalisation is 17.34M EUR.
Mauna Kea Technologies reports return on equity of -223.5%, an operating margin of -78.3% and revenue down 13.2% year over year.
Its debt exceeds its cash by 9.48M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.
No upcoming events tracked.